Rita Medical Systems Announces USPTO Confirms Key Claims in Patent No. 5,683,384
2006年2月27日 - 8:30PM
PRニュース・ワイアー (英語)
Key Technology Patent Includes Radiofrequency and Microwave Energy
Sources for the Purpose of Performing Ablation FREMONT, Calif.,
Feb. 27 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc.
(NASDAQ:RITA), a publicly-traded medical device company focused
solely on cancer therapies, today announced that the United States
Patent and Trademark Office (USPTO) has confirmed key patent claims
as amended in the U.S. Patent No. 5,683,384 relating to ablation
with radiofrequency (RF) and microwave technology. The '384 patent
was issued on November 4, 1997 and is the sole property of RITA
Medical Systems, Inc. The Company noted that during reexamination
proceedings at the USPTO, key patent claims in the '384 Patent were
amended to recite RF and microwave technology. In an Office
communication, the Patent Office stated that the prior art of
record in the reexamination of the '384 Patent did not anticipate
or make obvious the amended claims of the '384 Patent. Darrin
Uecker, Chief Technology Officer of RITA Medical commented, "We are
pleased that the patent office reached a positive conclusion
regarding key claims in the '384 patent. We believe the inclusion
of the use of microwave as well as radiofrequency energy to perform
ablations broadens RITA's intellectual property portfolio and is an
important component of ensuring RITA's continuing dominant position
in innovative ablation technologies." About RITA Medical Systems,
Inc. RITA Medical Systems develops, manufactures and markets
innovative products for cancer patients including radiofrequency
ablation (RFA) systems for treating cancerous tumors as well as
percutaneous vascular and spinal access systems. The Company's
oncology product lines include implantable ports, some of which
feature its proprietary Vortex(R) technology; tunneled central
venous catheters; and safety infusion sets and peripherally
inserted central catheters used primarily in cancer treatment
protocols. The product line also includes the HABIB 4X resection
device which coagulates a "surgical resection plane" and is
designed to facilitate a fast dissection in order to minimize blood
loss and blood transfusion during surgery. The proprietary RITA RFA
system uses radiofrequency energy to heat tissue to a high enough
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA Company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
again became the first company to receive specific FDA clearance,
this time for the palliation of pain associated with metastatic
lesions involving bone. The RITA Medical Systems website is at
http://www.ritamedical.com/. The statements in this news release
related to the Company's intellectual property portfolio, the
Company's competitive position in innovative ablation technologies,
and the Company's ability to develop, acquire or license new
products and services, are forward-looking statements involving
risks and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements. Such
risks and uncertainties include but are not limited to: the
Company's ability to protect its intellectual property rights;
potential infringement of the intellectual property rights of
others; the Company's historical and future operating results and
profitability; market acceptance of any new products or services of
the Company; competitive pressures; the development of alternative
therapies; physician training efforts; and general economic and
political conditions. Information regarding these risks and other
risks and uncertainties is included in the Company's filings with
the Securities and Exchange Commission. DATASOURCE: RITA Medical
Systems, Inc. CONTACT: investors, Doug Sherk, , or Jennifer
Beugelmans, both of EVC Group, +1-415-896-6820, for RITA Medical
Systems, Inc.; or Stephen Pedroff, VP Marketing Communications of
RITA Medical Systems, Inc., +1-510-771-0400, or ; or media, Steve
DiMattia of EVC Group, +1-646-277-8706, or , for RITA Medical
Systems, Inc. Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 5 2024 まで 6 2024
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Rita Medical Systems (ナスダック市場): 0 recent articles
その他のRita Medical Systems (MM)ニュース記事